DNA variants in cytokine and NOD2 genes, exposures to infections and risk for Crohn's disease

Paediatric and Perinatal Epidemiology

Volumn 17, Issue 3, 2003, Pages 302-312

  Amre, Devendra K ^a   Seidman, Ernest G ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA; GENE PRODUCT;

CHILD; CHILDHOOD DISEASE; CROHN DISEASE; CYTOKINE PRODUCTION; DEVELOPED COUNTRY; DNA DETERMINATION; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; GENETIC SUSCEPTIBILITY; HEREDITY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFANT; INFECTION RISK; INTRAUTERINE INFECTION; MOLECULAR GENETICS; NOD2 GENE; PATHOGENESIS; PATHOPHYSIOLOGY; POPULATION RISK; PREVALENCE; PREVENTIVE MEDICINE; REVIEW;

CARRIER PROTEINS; CHILD; CROHN DISEASE; CYTOKINES; DNA; ENVIRONMENTAL EXPOSURE; HUMANS; INFECTION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NOD2 SIGNALING ADAPTOR PROTEIN; RISK FACTORS;

EID: 0037675780     PISSN: 02695022     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3016.2003.00501.x     Document Type: Review

References (103)

1. Loftus EV, Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-93: incidence, prevalence, and survival. Gastroenterology 1998; 114:1161-1168.
2. Armitage E, Drummond H, Ghosh S, Ferguson A. Incidence of juvenile-onset Crohn's disease in Scotland, Lancet 1999; 353:1496-1497.
3. Grand RJ, Ramakrishna J, Calenda K. Inflammatory bowel disease in the pediatric patient. Gastroenterology Clinics of North America 1995; 24:613-632.
4. Scholmerich J. Inflammatory bowel disease at the end of its first century. Hepato-Gastroenterology 2000; 47:2-4.
5. Irwine EJ, Farrokhyar F, Swarbrick ET. A critical review of epidemiological studies in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2001; 36:2-15.
6. Russel MGVM, Stockbrügger RW. Epidemiology of inflammatory bowel disease: an update. Scandinavian Journal of Gastroenterology 1996; 31:417-427.
7. Jayanthi V, Probert CSJ, Pinder D, Wicks ACB, Mayberry JF. Epidemiology of Crohn's disease in Indian migrants and the indigenous population in Leicestershire. Quarterly Journal of Medicine 1992; 82:125-138.
8. Miller DS, Keighley A, Smith PG, Hughes AO, Langman MJ. Crohn's disease in Nottingham: a search for time-space clustering. Gut 1975; 16:454-457.
9. Cave DR, Freedman LS. Seasonal variation in clinical presentation of Crohn's disease and ulcerative colitis. International Journal of Epidemiology 1975; 4:317-320.
10. Ekbom A, Zack M, Adami HO, Helmick C. Is there clustering of inflammatory bowel disease at birth? American Journal of Epidemiology 1991; 134:876-886.
11. Comes MC, Gower RC, Colombel JF, Belaiche J, Van Kruiningen HJ, Nuttens MC, et al. Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liege county of Belgium. Gut 1994; 35:1316-1318.
12. Montgomery SM, Morris DL, Pounder RE, Wakefield AJ. Asian ethnic origin and the risk of inflammatory bowel disease. European Journal of Gastroenterology and Hepatology 1999; 11:543-546.
13. Ekbom A, Adami HO, Helmick CG, Jonzon A, Zack MM. Perinatal risk factors for inflammatory bowel disease: a case - control study. American Journal of Epidemiology 1990; 132:1111-1119.
14. Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn's disease, Lancet 1994; 344:508-510.
15. Ekbom A, Daszak P, Kraaz W, Wakefield AJ. Crohn's disease after in utero measles virus exposure. Lancet 1996; 348:515-517.
16. Nielsen LL, Nielsen NM, Melbye M, Sodermann M, Jacobsen M, Aaby P. Exposure to measles in utero and Crohn's disease: Danish register study, British Medical Journal 1998; 316:196-197.
17. Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV, Jr, Poland GA, Melton LJ, 3rd. Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease. Inflammatory Bowel Diseases 1999; 5:104-106.
18. Haslam N, Mayberry JF, Hawthorne AB, Newcombe RG, Holmes GK, Probert CS. Measles, month of birth, and Crohn's disease. Gut 2000; 47:801-803.
19. Thompson NP, Pounder RE, Wakefield AJ. Perinatal and childhood risk factors for inflammatory bowel disease: a case-control study. European Journal of Gastroenterology and Hepatology 1995; 7:385-390.
20. Thompson NP, Montgomery SM, Wadsworth MEJ, Pounder RE, Wakefield AJ, Early determinants of inflammatory bowel disease: use of two national longitudinal birth cohorts. European Journal of Gastroenterology 2000; 12:25-30.
21. Gilat T, Hacohen D, Lilos P, Langman MJS. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scandinavian Journal of Gastroenterology 1987; 22:1009-1024.
22. Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk of inflammatory bowel disease. Digestive Diseases and Sciences 1994; 39:555-560.
23. Montgomery SM, Morris DL, Pounder RE, Wakefield AJ. Paramyxovirus infections in childhood and subsequent inflammatory bowel disease. Gastroenterology 1999; 116:796-803.
24. Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV, Jr, Poland GA, Harmsen WS, et al. Early measles virus infection is associated with the development of inflammatory bowel disease. American Journal of Gastroenterology 2000; 95:1480-1485.
25. Gent AE, Hellier MD, Grace RH, Swarbrick ET, Coggon D. Inflammatory bowel disease and domestic hygiene in infancy. Lancet 1994; 343:766-767.
26. Duggan AE, Usmani I, Neal KR, Logan RFA. Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case-control study. Gut 1998; 43:494-498.
27. Corrao G, Tragnone A, Caprilli R, Trallori G, Papi C, Andreoli A, et al. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). International Journal of Epidemiology 1998; 27:397-404.
28. Smithson JE, Radford-Smith G, Jewell GP. Appendectomy and tonsillectomy in patients with inflammatory bowel disease. Journal of Clinical Gastroenterology 1995; 21:283-286.
29. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995; 345:1071-1074.
30. Feeney M, Clegg A, Winwood P, Snook J. A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group. Lancet 1997; 350:764-766.
31. Miller E, Waight P. Measles, measles vaccination, and Crohn's disease. Second immunisation has not affected incidence in England. British Medical Journal 1998; 316:1745.
32. Pebody RG, Paunio M, Ruutu P. Measles, measles vaccination, and Crohn's disease. Crohn's disease has not increased in Finland. British Medical Journal 1998; 316:1745-1746.
33. Bouma G, Xia B, Crusius JB, Bioque G, Koutroubakis I, Von Blomberg BM, et al. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clinical and Experimental Immunology 1996; 103:391-396.
34. Hirv K, Seyfarth M, Uibo R, Kull K, Salupere R, Latza U, et al. Polymorphisms in tumour necrosis factor and adhesion molecule genes in patients with inflammatory bowel disease: associations with HLA-DR and -DQ alleles and subclinical markers. Scandinavian Journal of Gastroenterology 1999; 34:1025-1032.
35. Plevy SE, Targan SR, Yang H, Fernandez D, Rotter JI, Toyoda H. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology 1996; 110:1053-1060.
36. Kawasaki A, Tsuchiya N, Hagiwara K, Takazoe M, Tokunaga K. Independent contribution of HLA-DRB1 and TNF alpha promoter polymorphisms to the susceptibility to Crohn's disease. Genes and Immunology 2000; 1:351-357.
37. Negoro K, Kinouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J, et al. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene. Gastroenterology 1999; 117:1062-1068.
38. Louis E, Satsangi J, Roussomoustakaki M, Parkes M, Fanning G, Welsh K, et al. Cytokine gene polymorphisms in inflammatory bowel disease. Gut 1996; 39:705-710.
39. Louis E, Peeters M, Franchimont D, Seidel L, Fontaine F, Demolin G, et al. Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour? Clinical and Experimental Immunology 2000; 119:64-68.
40. Nemetz A, Kope A, Molnar T, Kovacs A, Feher J, Tulassay Z, et al. Significant differences in the interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in a Hungarian population with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1999; 34:175-179.
41. Mwantembe O, Gaillard MC, Barkhuizen M, Pillay V, Berry SD, Dewar JB, et al. Ethnic differences in allelic associations of the interleukin-1 gene cluster in South African patients with inflammatory bowel disease (IBD) and in control individuals. Immunogenetics 2001; 52:249-254.
42. Aithal GP, Day CP, Leathart J, Daly AK, Hudson M. Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. Genes and Immunology 2001; 2:44-47.
43. Bioque G, Crusius JB, Koutroubakis I, Bouma G, Kostense PJ, Meuwissen SG, et al. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clinical and Experimental Immunology 1995; 102:379-383.
44. Hacker UT, Bidlingmaier C, Gomolka M, Keller E, Eigler A, Hartmann G, et al. Inflammatory bowel disease: no association between allele combinations of the interleukin (IL) I beta and IL-I receptor antagonist gene polymorphisms. European Journal of Clinical Investigation 1998; 28:214-219.
45. Tagore A, Gonsalkorale WM, Pravica V, Hajeer AH, McMahon R, Whorwell PJ, et al. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 1999; 54:386-390.
46. Parkes M, Satsangi J, Jewell D. Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility. Clinical and Experimental Immunology 1998; 113:28-32.
47. Klein W, Tromm A, Griga T, Fricke H, Folwaczny C, Hocke M, et al. The IL-10 gene is not involved in the predisposition to inflammatory bowel disease. Electrophoresis 2000; 21:3578-3582.
48. Aithal GP, Craggs A, Day CP, Welfare M, Daly AK, Mansfield JC, et al. Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflammatory bowel disease. Digestive Diseases and Sciences 2001; 46:1520-1525.
49. Klein W, Trornm A, Griga T, Fricke H, Folwaczny C, Hocke M, et al. The polymorphism at position -174 of the IL-6 gene is not associated with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology 2001; 13:45-47.
50. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
51. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606.
52. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357:1925-1928.
53. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJP, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122:867-874.
54. Vermeire S, Wild G, Kocher K, Cousineau J, Dufresne L, Bitton A, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. American Journal of Human Genetics 2002; 71:74-83.
55. Lesage S, Zouali H, Cézard JP, Colombel JF, Belaiche J, Almer S, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. American Journal of Human Genetics 2002; 70:845-857.
56. Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002; 359:1661-1665.
57. Murillo L, Crusius JBA, van Bodegraven AA, Alizadeh BZ, Pena AS. CARD 15 gene and the classification of Crohn's disease. Immunogenetics 2002; 54:59-61.
58. McClane SJ, Rombeau JL. Cytokines and inflammatory bowel disease: a review. Journal of Parenteral and Enteral Nutrition 1999; 23 (5 Suppl.):S20-S24.
59. Lundqvist C, Yeung MM, Hammarstrom S, Hammarstrom ML. Intraepithelial lymphocytes in human gut have lytic potential and a cytokine profile that suggests T helper 1 and cytotoxic functions. Journal of Immunology 1996; 157:1926-1934.
60. Carol M, Lambrechts A, Van Gossum A, Libin M, Goldman M, Mascart-Lemone F. Spontaneous secretion of interferon gamma and interleukin 4 by human intraepithelial and lamina propria gut lymphocytes. Gut 1998; 42:643-649.
61. Powrie F, Menon S, Coffman RL. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. European Journal of Immunology 1993; 23:2223-2229.
62. Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, et al. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunology Today 1997; 18:61-64.
63. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 1989; 30:835-838.
64. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. Journal of Immunology 1995; 154:2434-2440.
65. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32:913-917.
66. Kusugami K, Fukatsu A, Tanimoto M, Shinoda M, Haruta J, Kuroiwa A, et al. Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Digestive Diseases and Sciences 1995; 40:949-959.
67. Mitsuyama K, Toyonaga A, Sasaki E, Watanabe K, Tateishi H, Nishiyama T, et al. IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clinical and Experimental Immunology 1994; 96:432-436.
68. Mahida YR, Kurlac L, Gallagher A, Hawkey CJ. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1991; 32:1531-1534.
69. Kusugami K, Matsuura T, West GA, Youngman KR, Rachmilewitz D, Fiocchi C. Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease. Gastroenterology 1991; 101:1594-1605.
70. Karltunnen R, Breese EJ, Walker-Smith JA, MacDonald TT. Decreased mucosal interleukin-4 (IL-4) production in gut inflammation. Journal of Clinical Pathology 1994; 47:1015-1018.
71. Nielsen OH, Koppen T, Rudiger N, Horn T, Eriksen J, Kirman I. Involvement of interleukin-4 and -10 in inflammatory bowel disease. Digestive Diseases and Sciences 1996; 41:1786-1793.
72. Mullin GE, Maycon ZR, Braun-Elwert L, Cerchia R, James SP, Katz S, et al. Inflammatory bowel disease mucosal biopsies have specialized lymphokine mRNA profiles. Inflammatory Bowel Diseases 1996; 2:16-26.
73. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. Journal of Immunology 1996; 157:1261-1270.
74. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108:1434-1444.
75. Matsura T, West GA, Youngman KR, Klein JS, Fiocchi C. Immune activation genes in inflammatory bowel disease. Gastroenterology 1993; 104:448-458.
76. Romagnani S. T-cell subsets (Th1 versus Th2). Annals of Allergy, Asthma and Immunology 2000; 85:9-21.
77. Kitani A, Chua K, Nakamura K, Strober W. Activated self-MHC-reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. Journal of Immunology 2000; 165:691-702.
78. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-742.
79. Street NE, Schumacher JH, Fong TA, Bass H, Fiorentino DF, Leverah JA, et al. Heterogeneity of mouse helper T cells. Evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells. Journal of Immunology 1990; 144:1629-1639.
80. Rocken M, Saurat JH, Hauser C. A common precursor for CD4+ T cells producing IL-2 or IL-4. Journal of Immunology 1992; 148:1031-1036.
81. Kamogawa Y, Minasi LA, Carding SR, Bottomly K, Flavell RA. The relationship of IL-4- and IFN gamma-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 1993; 75:985-995.
82. Seder RA, Paul WE, Davis MM, Fazekas de St Groth B. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. Journal of Experimental Medicine 1992; 176:1091-1098.
83. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy KM. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proceedings of the National Academy of Sciences USA 1992; 89:6065-6069.
84. Paul WE, Seder RA, Plaut M. Lymphokine and cytokine production by Fc epsilon RI+ cells. Advances in Immunology 1993; 53:1-29.
85. Fitch FW, McKisic MD, Lancki DW, Gajewski TF. Differential regulation of murine T lymphocyte subsets. Annual Reviews of Immunology 1993; 11:29-48.
86. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76:241-251.
87. Bretscher PA, Wei G, Menon JN, Bielefeldt-Ohmann H. Establishment of stable, cell-mediated immunity that makes 'susceptible' mice resistant to Leishmania major. Science 1992; 257:539-542.
88. De Wit D, Van Mechelen M, Ryelandt M, Figueiredo AC, Abramowicz D, Goldman M, et al. The injection of deaggregated gamma globulins in adult mice induces antigen-specific unresponsiveness of T helper type 1 but not type 2 lymphocytes. Journal of Experimental Medicine 1992; 175:9-14.
89. Burstein HJ, Shea CM, Abbas AK. Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells. Journal of Immunology 1992; 148:3687-3691.
90. Prescott SL, Macaubas C, Holt BJ, Smallacombe TB, Loh R, Sly PD, et al. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T cell responses toward the Th2 cytokine profile. Journal of Immunology 1998; 160:4730-4737.
91. Elliott DE, Urban JF, Jr, Argo CK, Weinstock JV. Does the failure to acquire helminthic parasites predispose to Crohn's disease? FASEB (Federation of American Societies for Experimental Biology) Journal 2000; 14:1848-1855.
92. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. Journal of Biological Chemistry 2001; 276:4812-4818.
93. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998; 42:477-484.
94. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:182-205.
95. Beutler B. Autoimmunity and apoptosis: the Crohn's connection. Immunity 2001; 15:5-14.
96. Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121:1145-1157.
97. Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002; 123:106-111.
98. van Heel DA, Udalova IA, De Silva AP, McGovern DP, Kinouchi Y, Hull J, et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-kappaB transcription factors. Human Molecular Genetics 2002; 11:1281-1289.
99. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signalling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nature Medicine 2000; 6:583-588.
100. van Heel DA, Satsangi J, Carey AH, Jewell DP. Inflammatory bowel disease: progress towards a gene. Canadian Journal of Gastroenterology 2000; 14:207-219.
101. Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, McLeod RS, Griffiths AM, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. American Journal of Human Genetics 2000; 66:1863-1870.
102. Rioux JD, Daly MJ, Silverberg MS, Lindblad K, Steinhart H, Cohen Z, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn's disease. Nature Genetics 2001; 29:223-228.
103. Amre DK, Seidman EG. Etiopathogenesis of pediatric Crohn's disease. Biologic pathways based on interactions between genetic and environmental factors. Medical Hypotheses 2003; 60:344-350.